Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGB-BP-3 dose-ranging in CDAD
NCT03824795Phase 2Completed
- Sponsor
- MGB Biopharma
- Start
- Feb 2019
- Primary completion
- Apr 2020
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of MGB-BP-3 in Clostridium difficile infection (CDI) (3 arms), sponsored by MGB Biopharma. Primary endpoints: Number of participants with treatment-related adverse events at 40 days and Initial cure rate at 12 days. Started Feb 2019; status: completed.
02
Drugs
MGB-BP-3
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03824795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824795.